Equivalence trials in SLE research: Issues to consider

Mimi Kim, Jill P. Buyon, Michelle Petri, Mary Louise Skovron, Roy E. Shore

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In contrast to the objective of most clinical trials, which is to demonstrate superiority of an experimental treatment over a standard or placebo, the aim of an equivalence trial is to show that two treatments are equivalent in outcome or only marginally different. This would be of interest when an experimental treatment offers advantages such as reduced toxicity, ease of administration, or cost relative to the standard. Demonstrating equivalence may also be a goal when evaluating the safety of certain drugs because similarity in the risks of an adverse event in subjects exposed and unexposed to the drug is an indication of its safety. The classical formulation of the null hypothesis of treatment equality that is used in superiority trials is not applicable to equivalence trials because absolute equivalence between treatment groups cannot be proven. The strategy in equivalence trials is to define a maximum difference between treatment groups that is clinically acceptable and then assess whether there is sufficient evidence from the trial to conclude that the true treatment difference is within this acceptable range. In this paper, we discuss issues surrounding the planning, conduct, and analysis of equivalence trials in the context of SLE, with examples from the SELENA study.

Original languageEnglish (US)
Pages (from-to)620-626
Number of pages7
JournalLupus
Volume8
Issue number8
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Research
Therapeutics
Safety
Pharmaceutical Preparations
Placebos
Clinical Trials
Costs and Cost Analysis

Keywords

  • Clinical trials
  • Equivalence trials
  • Statistical methods
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Kim, M., Buyon, J. P., Petri, M., Skovron, M. L., & Shore, R. E. (1999). Equivalence trials in SLE research: Issues to consider. Lupus, 8(8), 620-626. https://doi.org/10.1191/096120399680411308

Equivalence trials in SLE research : Issues to consider. / Kim, Mimi; Buyon, Jill P.; Petri, Michelle; Skovron, Mary Louise; Shore, Roy E.

In: Lupus, Vol. 8, No. 8, 1999, p. 620-626.

Research output: Contribution to journalArticle

Kim, M, Buyon, JP, Petri, M, Skovron, ML & Shore, RE 1999, 'Equivalence trials in SLE research: Issues to consider', Lupus, vol. 8, no. 8, pp. 620-626. https://doi.org/10.1191/096120399680411308
Kim, Mimi ; Buyon, Jill P. ; Petri, Michelle ; Skovron, Mary Louise ; Shore, Roy E. / Equivalence trials in SLE research : Issues to consider. In: Lupus. 1999 ; Vol. 8, No. 8. pp. 620-626.
@article{4e20181eb0b34624b9388870c3733676,
title = "Equivalence trials in SLE research: Issues to consider",
abstract = "In contrast to the objective of most clinical trials, which is to demonstrate superiority of an experimental treatment over a standard or placebo, the aim of an equivalence trial is to show that two treatments are equivalent in outcome or only marginally different. This would be of interest when an experimental treatment offers advantages such as reduced toxicity, ease of administration, or cost relative to the standard. Demonstrating equivalence may also be a goal when evaluating the safety of certain drugs because similarity in the risks of an adverse event in subjects exposed and unexposed to the drug is an indication of its safety. The classical formulation of the null hypothesis of treatment equality that is used in superiority trials is not applicable to equivalence trials because absolute equivalence between treatment groups cannot be proven. The strategy in equivalence trials is to define a maximum difference between treatment groups that is clinically acceptable and then assess whether there is sufficient evidence from the trial to conclude that the true treatment difference is within this acceptable range. In this paper, we discuss issues surrounding the planning, conduct, and analysis of equivalence trials in the context of SLE, with examples from the SELENA study.",
keywords = "Clinical trials, Equivalence trials, Statistical methods, Systemic lupus erythematosus",
author = "Mimi Kim and Buyon, {Jill P.} and Michelle Petri and Skovron, {Mary Louise} and Shore, {Roy E.}",
year = "1999",
doi = "10.1191/096120399680411308",
language = "English (US)",
volume = "8",
pages = "620--626",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Equivalence trials in SLE research

T2 - Issues to consider

AU - Kim, Mimi

AU - Buyon, Jill P.

AU - Petri, Michelle

AU - Skovron, Mary Louise

AU - Shore, Roy E.

PY - 1999

Y1 - 1999

N2 - In contrast to the objective of most clinical trials, which is to demonstrate superiority of an experimental treatment over a standard or placebo, the aim of an equivalence trial is to show that two treatments are equivalent in outcome or only marginally different. This would be of interest when an experimental treatment offers advantages such as reduced toxicity, ease of administration, or cost relative to the standard. Demonstrating equivalence may also be a goal when evaluating the safety of certain drugs because similarity in the risks of an adverse event in subjects exposed and unexposed to the drug is an indication of its safety. The classical formulation of the null hypothesis of treatment equality that is used in superiority trials is not applicable to equivalence trials because absolute equivalence between treatment groups cannot be proven. The strategy in equivalence trials is to define a maximum difference between treatment groups that is clinically acceptable and then assess whether there is sufficient evidence from the trial to conclude that the true treatment difference is within this acceptable range. In this paper, we discuss issues surrounding the planning, conduct, and analysis of equivalence trials in the context of SLE, with examples from the SELENA study.

AB - In contrast to the objective of most clinical trials, which is to demonstrate superiority of an experimental treatment over a standard or placebo, the aim of an equivalence trial is to show that two treatments are equivalent in outcome or only marginally different. This would be of interest when an experimental treatment offers advantages such as reduced toxicity, ease of administration, or cost relative to the standard. Demonstrating equivalence may also be a goal when evaluating the safety of certain drugs because similarity in the risks of an adverse event in subjects exposed and unexposed to the drug is an indication of its safety. The classical formulation of the null hypothesis of treatment equality that is used in superiority trials is not applicable to equivalence trials because absolute equivalence between treatment groups cannot be proven. The strategy in equivalence trials is to define a maximum difference between treatment groups that is clinically acceptable and then assess whether there is sufficient evidence from the trial to conclude that the true treatment difference is within this acceptable range. In this paper, we discuss issues surrounding the planning, conduct, and analysis of equivalence trials in the context of SLE, with examples from the SELENA study.

KW - Clinical trials

KW - Equivalence trials

KW - Statistical methods

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0032758557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032758557&partnerID=8YFLogxK

U2 - 10.1191/096120399680411308

DO - 10.1191/096120399680411308

M3 - Article

C2 - 10568898

AN - SCOPUS:0032758557

VL - 8

SP - 620

EP - 626

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 8

ER -